Drug intelligence / Profile preview

amoxicillin + levofloxacin + vonoprazan fumarate

Development stage: Phase 4
Lead developer: Phathom Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of amoxicillin (antibiotic), levofloxacin (antibiotic), and vonoprazan fumarate (potassium-competitive acid blocker) used for the treatment of Helicobacter pylori infection. This combination leverages vonoprazan's potent acid suppression capabilities, which are stronger than traditional proton pump inhibitors, along with two antibiotics to effectively eradicate H. pylori bacteria, particularly in cases where antibiotic resistance may be a concern.

Other names: Vonoprazan + Levofloxacin-Based Triple TherapyCURE-H. Pylori Arm 3

Targets

DNA gyraseATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on amoxicillin + levofloxacin + vonoprazan fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + levofloxacin + vonoprazan fumarate.